Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells.
Ratings
0 / 5
0 ratings in the last 12 months
5
4
3
2
1
CEO
Mr. Robert J. Bitterman$3.2M
Market Cap • 25/04/20242011
(há 13 anos)
2012
(12 years ago)
NASDAQ
Listagem
Marlborough
Sede • Massachusetts10
N° de Empregados • 2022Valuation
Company FinancialsValuation Indicators
Valuation IndicatorsRetorno Histórico
PHIOSó no Premium...
Visualize o retorno de longo prazo das ações. Dividendos e outros eventos são considerados.